RPG Life Sciences Limited (RPGLIFE.BO)
INR 2228.1
(1.76%)
INR 2228.1
(1.76%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.28 Billion INR | 19.96% |
| 2022 | 1.08 Billion INR | 20.64% |
| 2021 | 902.4 Million INR | 24.7% |
| 2020 | 718.4 Million INR | 17.9% |
| 2019 | 555.7 Million INR | 74.99% |
| 2018 | 352.3 Million INR | -13.47% |
| 2017 | 394.2 Million INR | 37.41% |
| 2016 | 294.9 Million INR | 14.79% |
| 2015 | 242.3 Million INR | 45.78% |
| 2014 | 141.7 Million INR | 23.57% |
| 2013 | 155 Million INR | -17.55% |
| 2012 | 205 Million INR | -9.78% |
| 2011 | 188.2 Million INR | -43.43% |
| 2010 | 332.7 Million INR | 4.38% |
| 2009 | 318.72 Million INR | 20.99% |
| 2008 | 263.43 Million INR | 2.97% |
| 2007 | 255.84 Million INR | -3.26% |
| 2006 | 264.47 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 390.7 Million INR | 100.0% |
| 2023 Q1 | 322.4 Million INR | 81.63% |
| 2023 Q2 | 391.2 Million INR | 21.34% |
| 2023 FY | - INR | 19.96% |
| 2023 Q4 | 207.2 Million INR | -47.97% |
| 2023 Q3 | 398.2 Million INR | 1.79% |
| 2022 Q3 | 297.2 Million INR | -4.01% |
| 2022 Q4 | 177.5 Million INR | -40.28% |
| 2022 FY | - INR | 20.64% |
| 2022 Q2 | 309.6 Million INR | 6.54% |
| 2022 Q1 | 290.6 Million INR | 96.75% |
| 2021 Q3 | 247.1 Million INR | -6.79% |
| 2021 FY | - INR | 24.7% |
| 2021 Q4 | 147.7 Million INR | -40.23% |
| 2021 Q1 | 233.6 Million INR | 80.25% |
| 2021 Q2 | 265.1 Million INR | 13.48% |
| 2020 Q1 | 173 Million INR | 128.84% |
| 2020 FY | - INR | 17.9% |
| 2020 Q4 | 129.6 Million INR | -39.5% |
| 2020 Q3 | 214.2 Million INR | 11.8% |
| 2020 Q2 | 191.6 Million INR | 10.75% |
| 2019 Q2 | 165.6 Million INR | 6.77% |
| 2019 FY | - INR | 74.99% |
| 2019 Q1 | 155.1 Million INR | 122.53% |
| 2019 Q4 | 75.6 Million INR | -49.36% |
| 2019 Q3 | 149.3 Million INR | -9.84% |
| 2018 Q4 | 69.7 Million INR | -42.4% |
| 2018 FY | - INR | -13.47% |
| 2018 Q3 | 121 Million INR | 52.01% |
| 2018 Q2 | 79.6 Million INR | 8.59% |
| 2018 Q1 | 73.3 Million INR | -17.64% |
| 2017 FY | - INR | 37.41% |
| 2017 Q4 | 89 Million INR | -28.97% |
| 2017 Q3 | 125.3 Million INR | 3.04% |
| 2017 Q2 | 121.6 Million INR | 147.66% |
| 2017 Q1 | 49.1 Million INR | -13.56% |
| 2016 Q1 | 106.6 Million INR | 112.77% |
| 2016 FY | - INR | 14.79% |
| 2016 Q3 | 53.3 Million INR | -21.73% |
| 2016 Q2 | 68.1 Million INR | -36.12% |
| 2016 Q4 | 56.8 Million INR | 6.57% |
| 2015 Q2 | 59.3 Million INR | 5.33% |
| 2015 Q1 | 56.3 Million INR | -32.41% |
| 2015 FY | - INR | 45.78% |
| 2015 Q3 | 76.9 Million INR | 29.68% |
| 2015 Q4 | 50.1 Million INR | -34.85% |
| 2014 Q4 | 83.3 Million INR | 26.02% |
| 2014 FY | - INR | 23.57% |
| 2014 Q1 | 37.8 Million INR | 641.18% |
| 2014 Q2 | -37.7 Million INR | -199.74% |
| 2014 Q3 | 66.1 Million INR | 275.33% |
| 2013 Q2 | 45.9 Million INR | 108.35% |
| 2013 FY | - INR | -17.55% |
| 2013 Q4 | 5.1 Million INR | 121.34% |
| 2013 Q3 | -23.9 Million INR | -152.07% |
| 2013 Q1 | -550 Million INR | -784.08% |
| 2012 FY | - INR | -9.78% |
| 2012 Q2 | 46.5 Million INR | -32.61% |
| 2012 Q1 | 69 Million INR | 0.0% |
| 2012 Q4 | 80.4 Million INR | 541.76% |
| 2012 Q3 | -18.2 Million INR | -139.14% |
| 2011 FY | - INR | -43.43% |
| 2010 FY | - INR | 4.38% |
| 2009 FY | - INR | 20.99% |
| 2008 FY | - INR | 2.97% |
| 2007 FY | - INR | -3.26% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 89.801% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -87.755% |
| Sigachi Industries Limited | 883.39 Million INR | -45.065% |
| Bal Pharma Limited | 345.59 Million INR | -270.813% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 81.324% |
| Medico Remedies Limited | 150.37 Million INR | -752.186% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2069.115% |
| Venus Remedies Limited | 711.8 Million INR | -80.036% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 134.345% |
| Alpa Laboratories Limited | 86.12 Million INR | -1387.919% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 18.052% |
| Shilpa Medicare Limited | 2.58 Billion INR | 50.483% |
| Aarti Drugs Limited | 3.24 Billion INR | 60.553% |
| Lupin Limited | 36.96 Billion INR | 96.534% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.926% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.721% |
| Windlas Biotech Limited | 781.72 Million INR | -63.933% |
| Suven Life Sciences Limited | -992.78 Million INR | 229.082% |
| Eris Lifesciences Limited | 6.98 Billion INR | 81.657% |
| Valiant Laboratories Limited | 12.73 Million INR | -9959.659% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 86.272% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 145.413% |
| Ipca Laboratories Limited | 13.29 Billion INR | 90.364% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 13.355% |
| Achyut Healthcare Limited | 524 Thousand INR | -244461.069% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.074% |
| Bajaj HealthCare Limited | 444.51 Million INR | -188.291% |
| Mankind Pharma Limited | 28.09 Billion INR | 95.439% |
| Laurus Labs Limited | 8 Billion INR | 83.993% |
| Piramal Pharma Limited | 13.05 Billion INR | 90.184% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -197.832% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 96.34% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 86.674% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 88.703% |
| Unichem Laboratories Limited | 742.35 Million INR | -72.626% |
| Sequent Scientific Limited | 549.8 Million INR | -133.085% |
| Novartis India Limited | 1.26 Billion INR | -0.961% |
| Wanbury Limited | 985.49 Million INR | -30.037% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 72.601% |
| Wockhardt Limited | 1.08 Billion INR | -18.657% |
| Themis Medicare Limited | 562.6 Million INR | -127.779% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -296.185% |
| Jubilant Pharmova Limited | 8 Billion INR | 83.993% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 81.327% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.548% |
| Divi's Laboratories Limited | 25.43 Billion INR | 94.961% |
| NATCO Pharma Limited | 18.79 Billion INR | 93.182% |
| Gufic Biosciences Limited | 1.48 Billion INR | 13.441% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 50.836% |
| Ind-Swift Limited | 1.06 Billion INR | -20.321% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 57.487% |
| FDC Limited | 4.4 Billion INR | 70.886% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1649.071% |
| Granules India Limited | 8.6 Billion INR | 85.105% |
| Medicamen Biotech Limited | 245.66 Million INR | -421.656% |
| Alkem Laboratories Limited | 24.19 Billion INR | 94.703% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 45.625% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -9710.902% |
| Brooks Laboratories Limited | 41.72 Million INR | -2971.079% |
| Megasoft Limited | 284.73 Million INR | -350.074% |
| ZIM Laboratories Limited | 462.09 Million INR | -177.323% |
| Strides Pharma Science Limited | 3.76 Billion INR | 65.96% |
| Neuland Laboratories Limited | 4.74 Billion INR | 73.011% |
| Morepen Laboratories Limited | 1.72 Billion INR | 25.751% |
| Hikal Limited | 2.69 Billion INR | 52.4% |
| Indoco Remedies Limited | 2.64 Billion INR | 51.588% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 67.22% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -345.855% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -632.512% |
| Hester Biosciences Limited | 539.47 Million INR | -137.548% |